These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19877579)

  • 1. The heparin binding motif of endostatin mediates its interaction with receptor nucleolin.
    Fu Y; Chen Y; Luo X; Liang Y; Shi H; Gao L; Zhan S; Zhou D; Luo Y
    Biochemistry; 2009 Dec; 48(49):11655-63. PubMed ID: 19877579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
    Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
    Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells.
    Zhuo W; Luo C; Wang X; Song X; Fu Y; Luo Y
    J Pathol; 2010 Nov; 222(3):249-60. PubMed ID: 20814900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The nuclear translocation of endostatin is mediated by its receptor nucleolin in endothelial cells.
    Song N; Ding Y; Zhuo W; He T; Fu Z; Chen Y; Song X; Fu Y; Luo Y
    Angiogenesis; 2012 Dec; 15(4):697-711. PubMed ID: 22711211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin.
    Shi H; Huang Y; Zhou H; Song X; Yuan S; Fu Y; Luo Y
    Blood; 2007 Oct; 110(8):2899-906. PubMed ID: 17615292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endostatin phenylalanines 31 and 34 define a receptor binding site.
    Stahl S; Gaetzner S; Mueller TD; Felbor U
    Genes Cells; 2005 Sep; 10(9):929-39. PubMed ID: 16115201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
    Sasaki T; Larsson H; Kreuger J; Salmivirta M; Claesson-Welsh L; Lindahl U; Hohenester E; Timpl R
    EMBO J; 1999 Nov; 18(22):6240-8. PubMed ID: 10562536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleolin is a sequence-specific RNA-binding protein: characterization of targets on pre-ribosomal RNA.
    Ghisolfi-Nieto L; Joseph G; Puvion-Dutilleul F; Amalric F; Bouvet P
    J Mol Biol; 1996 Jul; 260(1):34-53. PubMed ID: 8676391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
    Beck MT; Chen NY; Franek KJ; Chen WY
    Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans.
    Reis RC; Schuppan D; Barreto AC; Bauer M; Bork JP; Hassler G; Coelho-Sampaio T
    Biochem Biophys Res Commun; 2005 Aug; 333(3):976-83. PubMed ID: 15985216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 beta.
    Koopmann W; Ediriwickrema C; Krangel MS
    J Immunol; 1999 Aug; 163(4):2120-7. PubMed ID: 10438952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zinc-binding of endostatin is essential for its antiangiogenic activity.
    Boehm T; O'reilly MS; Keough K; Shiloach J; Shapiro R; Folkman J
    Biochem Biophys Res Commun; 1998 Nov; 252(1):190-4. PubMed ID: 9813168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endostatin has ATPase activity, which mediates its antiangiogenic and antitumor activities.
    Wang S; Lu XA; Liu P; Fu Y; Jia L; Zhan S; Luo Y
    Mol Cancer Ther; 2015 May; 14(5):1192-201. PubMed ID: 25788476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin.
    Zhang X; Xu J; Lawler J; Terwilliger E; Parangi S
    Clin Cancer Res; 2007 Jul; 13(13):3968-76. PubMed ID: 17606731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of N-terminal region residues Lys11, Arg13, and Arg24 of antithrombin in heparin recognition and in promotion and stabilization of the heparin-induced conformational change.
    Schedin-Weiss S; Desai UR; Bock SC; Olson ST; Björk I
    Biochemistry; 2004 Jan; 43(3):675-83. PubMed ID: 14730971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of the N-terminal fragment of the antiangiogenic protein endostatin: a molecular dynamics study.
    Torres PH; Sousa GL; Pascutti PG
    Proteins; 2011 Sep; 79(9):2684-92. PubMed ID: 21769939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleolar localization of aprataxin is dependent on interaction with nucleolin and on active ribosomal DNA transcription.
    Becherel OJ; Gueven N; Birrell GW; Schreiber V; Suraweera A; Jakob B; Taucher-Scholz G; Lavin MF
    Hum Mol Genet; 2006 Jul; 15(14):2239-49. PubMed ID: 16777843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N-terminal integrity is critical for the stability and biological functions of endostatin.
    Fu Y; Luo Y
    Biochemistry; 2010 Aug; 49(30):6420-9. PubMed ID: 20545324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent.
    Cho H; Kim WJ; Lee YM; Kim YM; Kwon YG; Park YS; Choi EY; Kim KW
    Oncol Rep; 2004 Jan; 11(1):191-5. PubMed ID: 14654925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleolin targeting AS1411 modified protein nanoparticle for antitumor drugs delivery.
    Wu J; Song C; Jiang C; Shen X; Qiao Q; Hu Y
    Mol Pharm; 2013 Oct; 10(10):3555-63. PubMed ID: 23679916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.